Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Luo ilmainen tunnus

Generic Sweden

45,10 SEK

−0,33 %

Alle 1K seuraajaa

GENI

First North Stockholm

IT Services

Technology

Yleiskuva
Luvut & ennusteet
Omistajat
Sijoittajakonsensus
Vertaa
−0,33 %
−6,33 %
−14,58 %
−26,19 %
−18,00 %
+3,68 %
+25,63 %
−10,52 %
+90,34 %

Generic Sweden operates in the IT sector. The company offers a platform for digital communication services that are integrated into customers' internal or external communication flows. The services are provided through a CPaaS model (Communication Platform as a Service). The company's customers are found in several sectors with a particular position in alarms and security, healthcare and e-health, and e-commerce. The company was founded in 1993 and is headquartered in Stockholm.

Lue lisää
Markkina-arvo
554,37 milj. SEK
Vaihto
149,03 t. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Liikevaihto ja EBIT-%

Liikevaihto milj.

EBIT-% (oik.)

EPS ja Osinko

EPS (oik.)

Osinko %

Pörssikalenteri
12.11.
2025

Osavuosikatsaus Q3'25

12.2.
2026

Vuosikatsaus '25

13.5.
2026

Osavuosikatsaus Q1'26

Kaikki
Kolmansien osapuolien sisällöt
NäytäKaikki sisältötyypit
Kolmannen osapuolen analyysi21.10.2025 klo 5.26

Generic: Margin stability in a softer market - ABG

* Seasonally weaker volumes to weigh on earnings* 10-12% '26e-'27e sales growth, 21-22% EBIT margin* Trading at 12x EV/EBITA in '26e, ~15% below historical medianExpect usual seasonal impact on Q3 numbersGeneric reports its Q3'25 on 12 November, and ...

Generic Sweden
Kolmannen osapuolen analyysi25.8.2025 klo 5.27

Generic: Communication flows, margin grows - ABG

* Gross margin at 45% (40%)* SaaS supports margins and outlook* Trading at ~11-9x EV/EBITA for '26e-'27eStrong margin improvementGeneric reported sales of SEK 44m, up 2% y-o-y (4% below ABGSCe), driven by: i) lower volume-based products (e.g. SMS), which...

Generic Sweden
Kolmannen osapuolen analyysi21.8.2025 klo 8.03

Generic: Margins holding up well - ABG

* Sales -4% and adj. EBIT -11% vs ABGSCe* DOCS adoption >23% of municipalities* Consensus adj. EBIT likely down by mid single-digitsQ2'25 detailsGeneric reports Q2'25 sales of SEK 44.3m (-4% vs ABGSCe 46.2m), impacted by mix effects and smaller-sized...

Generic Sweden

Liity Inderesin yhteisöön

Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.

FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Luo ilmainen tunnus
Kolmannen osapuolen analyysi23.5.2025 klo 12.28

Generic: Scalability on show - ABG

6% organic sales growth y-o-y SaaS momentum drives gross margin uplift... ... and leads to impressive EBIT growth of 41% y-o-y Q1: Sales growth of 6%, EBIT margin of 21.7% (16.3%) The Q1 report really showed the scalability of Generic's business model...

Generic Sweden
Kolmannen osapuolen analyysi18.2.2025 klo 10.48

Generic: Ends 2024 in style - ABG

24% organic sales growth y-o-y Improved gross margin due to pricing and mix Opex flat y-o-y leads to 48% EBIT growth Q4: Sales growth of 24%, EBIT margin of 22.7% (19.0%) Generic continued its impressive comeback in Q4, where H1'24 profitability issues...

Generic Sweden
Kolmannen osapuolen analyysi15.11.2024 klo 14.52

Generic: Strong quarter and outlook - ABG

24% organic sales growth y-o-y Improved gross margin due to price adjustments Opex growth to abate in the coming quarters Q3: Sales growth of 24%, EBIT margin of 20.6% (22.6%) In our view, Generic's Q3 results were impressive. Sales growth remained strong...

Generic Sweden
Kolmannen osapuolen analyysi23.8.2024 klo 5.30

Generic: Strong growth, temporarily lower profitability - ABG

26% organic sales growth y-o-y Growth initiatives hurt profitability mid-term Pricing to act as a tailwind for gross margin in Q3 Q2: Sales growth of 26%, EBIT margin of 15.5% (20%) There was a similar trend in Generic's Q2 numbers as we saw in Q1, where...

Generic Sweden
Kolmannen osapuolen analyysi17.5.2024 klo 9.45

Generic: Prioritising growth over margins - ABG

22% organic sales growth y-o-y Lower than expected gross margin Price increases should help gross margin in Q2 Q1: Sales growth of 22%, EBIT margin of 16.3% (21.3%) Generic's Q1 numbers were quite eventful as there was a new strategic direction prioritising...

Generic Sweden
Kolmannen osapuolen analyysi22.2.2024 klo 7.38

Generic: 2024 outlook still looks solid - ABG

12% organic sales growth y-o-y Opex increase and IAC affect Q4 Profitability assumptions down on slightly higher opex Q4: Sales growth of 12%, adj. EBIT margin of 19% (21.5%) Generic reported Q4 numbers were slightly behind our expectations. Net sales...

Generic Sweden
Kolmannen osapuolen analyysi22.11.2023 klo 6.24

Generic: Solid Q3, softer outlook for '24e - ABG

15% organic sales growth y-o-y Inera volumes slightly delayed Minimal changes to long-term estimates Q3: Sales growth of 15%, EBIT margin of 22.6% (22.2%) Generic reported solid Q3 numbers with net sales of SEK 34.7m (+15% y-o-y, all organic), as the...

Generic Sweden
Kolmannen osapuolen analyysi9.11.2023 klo 14.23

Generic: Inera deal sets up exciting 2024 - ABG

We expect a solid Q3 with 12% organic sales growth 15% EBIT growth y-o-y in Q3e Inera framework agreement behind our revisions Q3e: gradual recovery to continue Generic has historically showed a stable development that stems from a recurring SaaS offering...

Generic Sweden
Kolmannen osapuolen analyysi30.8.2023 klo 5.33

Generic: Impressive profitability in Q2 - ABG

Solid sales growth at 10.4% y-o-y, all organic EBIT growth of 28% with excellent cost control Demand is holding up well into H2 Q2: Sales growth of 10.4%, EBIT margin of 20% (17.2%) Generic reported a solid quarter with net sales of SEK 34.6m (+10.4%...

Generic Sweden
Kolmannen osapuolen analyysi23.5.2023 klo 5.27

Generic: Shows scalability despite lower sales growth - ABG

Sales growth below 10% again, but comps were tough Delivers 18% EBIT growth y-o-y DOCS sales have stabilised the gross margin Q1: Sales growth of 9% and an EBIT margin of 21.3% (19.6%) Generic reported Q1 net sales of SEK 34.6m (+9% y-o-y, all organic...

Generic Sweden
Kolmannen osapuolen analyysi17.2.2023 klo 13.30

Generic: Sales growth re-established above 10% - ABG

Finding a new level of growth post COVID-19 Impressive profitability in Q4 Low churn confirmed, as expected Q4: Sales growth of 12% and an EBIT margin of 21.5% Generic reported solid Q4 results with net sales of SEK 34.2m (+12% y-o-y). Growth picked ...

Generic Sweden
Kolmannen osapuolen analyysi30.8.2022 klo 7.12

Generic: A rare miss in Q2 - ABG

Slower sales growth than we have become used toWe lower long-term EBIT by 5%Lifted COVID-19 restrictions boost new salesQ2: Net sales +6% y-o-y, EBIT margin of 17.2% (20.4%)Generic reported Q2 net sales of SEK 31.3m (29.6), representing a slower growth...

Generic Sweden
Kolmannen osapuolen analyysi21.2.2022 klo 10.47

Generic: Solid end to a fantastic year - ABG

Still growing sales >30% y-o-y in Q4Gross margin declining faster than expectedOpex will likely grow faster in ‘22e than ’20-‘21Q4: Sales +33% y-o-y, EBIT margin of 16.8% (15.9%)Generic reported Q4 net sales of SEK 30.5m (+33% y-o-y), 2% ahead of ABGSCe...

Generic Sweden
Kolmannen osapuolen analyysi24.11.2021 klo 11.19

Generic: Solid Q3, but growth falls short of high hopes - ABG

39% sales growth y-o-y, EBIT +50% y-o-ySequential sales decline behind estimate revisions’22e EV/EBIT of 45x, 1.4% dividend yieldGeneric reported Q3 net sales of SEK 27.2m (+39% y-o-y), 4% below our forecast. The deviation stems from a higher sequential...

Generic Sweden
Kolmannen osapuolen analyysi31.8.2021 klo 7.45

Generic: Q2 performance like clockwork - ABG

Two consecutive quarters with 47% y-o-y sales growthWe raise both sales and margin assumptions‘22e EV/EBIT of 38.2x, div yield of 1.6%Generic reported Q2 net sales of SEK 29.6m (20.2m), a second consecutive quarter with 47% y-o-y sales growth despite...

Generic Sweden
Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.